Figure 3.
(A) Tumor growth inhibition of saline (blue), free paclitaxel and everolimus (PTX+EVER) (green), and dual-targeted PTX+EVER-loaded nanoparticles (Dual-NPs) (red) in female NOD/SCID mice bearing MDA-MB-231-H2N BC xenografts (HER2mod/EGFRmod) after intravenous administration of treatments at a PTX-equivalent dose of 15 mg/kg and EVER-equivalent dose of 7.5 mg/kg once a week for eight consecutive weeks. Data represent mean ± SD (n = 8). Two-way analysis of variance (ANOVA) was conducted where ** and *** indicate p = 0.001 and p = 0.0003, respectively. (B) Kaplan-Meier survival analysis.